An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A person in their mid-40s with autoimmune inflammation and a history of using various peptides asked whether to microdose "Tirz" or "Reta," mentioning concerns about constipation because they already have slow gut motility from hypermobile Ehlers–Danlos syndrome (hEDS). They’ve used a bunch of other peptides in the past and currently take thymosin alpha‑1 and KPV. They’ve read that Tirz might be better for inflammation while Reta might help preserve muscle mass, and they want to know which one is less likely to cause constipation. First, a quick plain-English note about the two names. The shorthand here is a bit unclear because different peptide nicknames get used informally online. “Tirz” often refers to tirzepatide, a prescription drug sold as Mounjaro (used for diabetes and weight loss) that acts like two gut hormones to lower appetite and blood sugar. “Reta” likely refers to retatrutide, an experimental drug similar to tirzepatide but designed to hit three hormone pathways and is still in clinical trials. Both are not simple vitamins or homeopathic remedies — they’re engineered peptides that mimic natural gut hormones to change appetite, metabolism, and how the body handles nutrients. The research comparing them is limited and mostly comes from clinical trials, not personal anecdotes. Tirzepatide (the approved drug) has been tested in many people and shows strong effects on weight loss and blood sugar control; it can also reduce some inflammatory markers in some studies, but that’s not its main use. Retatrutide is earlier-stage and looked promising in research for producing larger weight loss and possibly better effects on metabolism and muscle preservation, but the data are from controlled trials with limited numbers of participants and short follow-ups compared with decades of clinical experience for older drugs. Importantly, neither was studied primarily as a treatment for autoimmune inflammation, and the direct anti‑inflammatory benefits in people with autoimmune diseases remain uncertain. For someone worried about constipation and slow gut motility from hEDS, practical takeaways matter. Both tirzepatide and retatrutide influence gut hormones and commonly cause gastrointestinal side effects. With tirzepatide, constipation is reported by some users, along with nausea and diarrhea; overall, digestive symptoms are among the most common side effects. The experimental data for retatrutide suggest similar GI effects, and because it may be even more potent, it could carry equal or greater risk of constipation, but we don’t have large, long-term safety data yet. So if slow motility is already a problem, introducing one of these drugs could make constipation worse for some people. There are important caveats. These drugs are prescription medications or experimental agents — they aren’t guaranteed safe for people with autoimmune diseases or connective‑tissue disorders like hEDS. You should not start or switch to them without a doctor’s guidance. People with severe slow‑gut symptoms, a history of bowel obstructions, or certain other medical conditions may be at higher risk. Side effects can include nausea, vomiting, diarrhea, constipation, gallbladder issues, and possible interactions with other medications. Retatrutide’s full safety profile isn’t established yet because it’s still in clinical trials. If you’re considering microdosing, discuss it with a clinician who knows your autoimmune condition, current meds, and GI history. Bottom line: both drugs can cause GI side effects, and because retatrutide is newer and possibly stronger, it might not be safer for constipation. Talk to your doctor — weigh the uncertain anti‑inflammatory benefits against the real risk of worsening slow gut motility before trying either one.
Source: r/Peptides